X

Download Effect of RHDL on Atherosclerosis-Safety PowerPoint Presentation

SlidesFinder-Advertising-Design.jpg

Login   OR  Register
X


Iframe embed code :



Presentation url :

Home / Health & Wellness / Health & Wellness Presentations / Effect of RHDL on Atherosclerosis-Safety PowerPoint Presentation

Effect of RHDL on Atherosclerosis-Safety PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

PowerPoint is the world's most popular presentation software which can let you create professional Effect of RHDL on Atherosclerosis-Safety powerpoint presentation easily and in no time. This helps you give your presentation on Effect of RHDL on Atherosclerosis-Safety in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Effect of RHDL on Atherosclerosis-Safety powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in Health & Wellness ppt presentation category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

About This Presentation

Slide 1 - The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific Session 2007 Presented by Dr. Jean-Claude Tardif, M.D. ERASE Trial
Slide 2 - ERASE Trial: Background CSL-111 is an apolipoprotein A-I isolated from human plasma and phosphatidylcholine derived from soybean. Commercial development of the cholesteryl ester transfer protein inhibitor torcetrapib was recently stopped after a trial showed an increase in mortality with torcetrapib. ACC 2007
Slide 3 - ERASE Trial: Background CSL-111 is a different class of agents targeting increasing HDL and is not a CETP inhibitor but is derived from human plasma. The goal of this trial was to evaluate the effect of plaque burden of reconstituted HDL compared with placebo among patients with recent acute coronary syndromes. ACC 2007
Slide 4 - CSL-111 40 mg/kg n=111 ERASE Trial: Study Design CSL-111 80 mg/kg n=12 Placebo Matching Dose n=60 183 patients aged 30-75 years with clinical need for coronary angiography, defined as ≥ 1 narrowing ≥20% coronary angiography at baseline; within 2 weeks of having an acute coronary syndrome defined as unstable angina or non-ST-segment or ST-segment elevation MI Placebo-controlled. Randomized. Double-blinded. Mean follow-up: 6 weeks. 17% female. ACC 2007 Primary Endpoint: Percentage change in atheroma volume from baseline to 6 weeks Secondary Endpoint: Absolute change in plaque volume, change in plaque characterization indexes on IVUS, and change in coronary score on quantitative coronary angiography. 80 mg group discontinued 6 week follow-up R
Slide 5 - ERASE Trial: Primary Endpoint Percent Change in Atheroma Volume from Baseline to 6 weeks The primary endpoint of percent change in atheroma volume from baseline to 6 weeks did not differ between treatment groups (-3.4% in the CSL-111 group vs. -1.6% in the placebo group, p=0.48) Placebo CSL-111 Change in atheroma volume (%) ACC 2007 p = 0.48
Slide 6 - ERASE Trial: Secondary Endpoint Absolute Change in Atheroma Volume from Basleine to 6 weeks The absolute change in atheroma volume from baseline to 6 weeks also did not differ between treatment groups (-5.3mm3 in the CSL-111 group vs. -2.3 mm3 in the placebo group, p=0.39) Placebo CSL-111 Absolute change in atheroma volume (mm3) ACC 2007 p = 0.39
Slide 7 - ERASE Trial: Secondary Endpoints Mean change in plaque characterization index on IVUS was -0.0097 for CSL-111 and +0.0128 for placebo (p=0.01). Reduction in coronary score on angiography was significantly less with CSL-111 compared with placebo (-0.039 mm for CSL-111 vs. -0.071 mm for placebo, p=0.03). ACC 2007
Slide 8 - ERASE Trial: Limitations The 80 mg CSL-111 group was discontinued due to high rates of abnormal liver function tests, including alanine aminotransferase >5 times the upper limit of normal (ULN) in 50% of the group and aspartate aminotransferase >5 times ULN in 33% of the group. The lipid effects of the agent in the study were not reported. A larger trial would be required to evaluate the clinical safety and efficacy of this agent. ACC 2007
Slide 9 - ERASE Trial: Summary Among patients with recent acute coronary syndromes, treatment with the novel reconstituted HDL agent CSL-111 was not associated with a reduction in atheroma volume compared with placebo. Treatment with CSL-111 was associated with a change in atheroma volume within the treatment arm from baseline to 6 week follow-up. ACC 2007
 

Frequently Asked Questions

> About SlidesFinder?

Slidesfinder is a website that allows users to upload and share their PowerPoint presentations online. It provides a platform for individuals and businesses to share their ideas and knowledge through presentations, and for others to view and download these presentations for educational or professional purposes.
Slidesfinder offers a wide range of presentation topics and categories, including business, education, science, technology, health, and more. Users can also search for presentations using keywords, tags, or by category. The website provides tools to create professional presentations with rich media, animations, and graphics.



One of the key features of Slidesfinder is its user-friendly interface, which allows users to easily upload, view, and share presentations. Users can also embed their presentations in their websites or blogs using the website's embed code feature.
Slidesfinder also offers premium services, such as the ability to create private presentations and to download presentations in high-quality formats. However, the basic features of Slidesfinder are free to use, making it accessible to anyone who wants to share their ideas and knowledge through presentations.

> How do I register with SlidesFinder?

Go to registration page (you can see signup link on top of website page) https://www.slidesfinder.com/signup . If you have facebook/gmail account them just click on SIGN IN WITH FACEBOOK OR SIGN IN WITH GOOGLE button, by this you will be a registered member of slidesfinder without filling any form, required detail automatically will be fatch from your account. If you do not a Facebook account, then click on "Signup". Fill all required fields and you will be a registered member of slidesfinder.

> Is slidesfinder account confirmation is mandatory?

Yes it is mandetory to active your account to login.

> Do I need to signup/login on SlidesFinder before uploading a PowerPoint presentation?

Yes, you need to login with your account before uploading presentation. Your username will be displayed on your uploaded presentation. Your registered email id is needed for sending your stats of uploaded presentation.

Slidesfinder is a sharing website for PowerPoint presentations search and share. Find your interest in the form of powerpoint presentations on slidesfinder and save your valuable time . On Slidesfinder you get presentations from our huge library of professional ppt presentations. We believe in making your search INFORMATIVE and FUN. Find your best ppt presentation from a pool of PowerPoint presentations stacked under important industry categories like business & management, heath & Wellness,eduction & training etc. We provide unique informative PowerPoint presentation for marketers, presenters and educationists. These professional PowerPoint presentations are uploaded by professionals from across numerous industry segments.These ppt presentations are available for FREE download.

Not just finding your interest, but facilitate you broadcast your interest. We have created this platform for easy sharing of PowerPoint presentations, ensuring that these presentations get maximum exposure. Create your slidesfinder account and upload PowerPoint presentations for free, share on social media platforms and BUILD YOUR CROWD WITH PRESENTATION !!

The Great Buddha says, "Share your knowledge.It’s a way to achieve immortality"! So, start sharing knowledge and we are here to make that immortal !!

© 2013-2022 SlidesFinder. All rights reserved.

Re-productivity of content are not allowed. Without prior written permission from author, commercial use of any content is illegal.